Patents Assigned to KYOWA KIRIN CO., LTD.
-
Publication number: 20230090939Abstract: An object of the present invention is to provide an anti-BMP10 antibody, and a therapeutic agent for hypertension and a hypertensive disease, containing the antibody as an active ingredient. The present invention relates to an anti-BMP10 monoclonal antibody or an antibody fragment thereof that binds to human BMP10 (bone morphogenetic protein 10). Further, the present invention relates to a therapeutic agent for hypertension and a hypertensive disease containing an antagonist for at least one of BMP10 and a BMP9/BMP10 heterodimer, a diagnostic agent or a pharmaceutical composition for a disease associated with human BMP10, an immunological detection method or a measurement method for human BMP10 using the antagonist, and use of the antagonist for producing a pharmaceutical composition for treating hypertension and a hypertensive disease.Type: ApplicationFiled: September 27, 2022Publication date: March 23, 2023Applicant: Kyowa Kirin Co., Ltd.Inventors: Hiroyuki ARIYAMA, Shinya OGAWA, Tetsuya KITAYAMA, Takenao YAMADA
-
Publication number: 20230073999Abstract: An object of the present invention is to provide a polynucleotide having a modification site in a translated region with translation activity retained. The object can be achieved by a polynucleotide containing a translated region from a start codon to a stop codon, in which the translated region contains n codons, and the n is a positive integer of 2 or more, each of the n codons contains first, second and third nucleotides, and the first nucleotides in at least two codons of the n codons are sugar modified nucleotides.Type: ApplicationFiled: December 25, 2020Publication date: March 9, 2023Applicants: National University Corporation Tokai National Higher Education and Research System, Kyowa Kirin Co., Ltd.Inventors: Hiroshi ABE, Hiroto IWAI, Masakazu HOMMA, Kana ASANO, Kenji HARADA, Junichiro YAMAMOTO, Fumikazu SHINOHARA, Keiichi MOTOSAWA, Yasuaki KIMURA, Kosuke NAKAMOTO
-
Patent number: 11591344Abstract: A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: (wherein, L1 and L2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).Type: GrantFiled: March 29, 2019Date of Patent: February 28, 2023Assignee: KYOWA KIRIN CO., LTD.Inventors: Kenji Uchida, Ryohei Kawai, Keisuke Yamamoto, Toshimi Kanai, Hideo Ikota, Takashi Imaeda, Kei Yoshida
-
Publication number: 20220378923Abstract: The present invention provides a BET (protein) degrader, specifically a BET degrader containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof: wherein L1 and L2 are the same or different and each represents a small molecular ligand for BET protein, and S represents a group represented by a formula selected from the group consisting of formulas (S1) to (S18).Type: ApplicationFiled: September 30, 2020Publication date: December 1, 2022Applicant: KYOWA KIRIN CO., LTD.Inventors: Keisuke YAMAMOTO, Toshimi KANAI, Kei YOSHIDA, Takashi IMAEDA, Masahiro ESAKI
-
Patent number: 11485779Abstract: An object of the present invention is to provide an anti-BMP10 antibody, and a therapeutic agent for hypertension and a hypertensive disease, containing the antibody as an active ingredient. The present invention relates to an anti-BMP10 monoclonal antibody or an antibody fragment thereof that binds to human BMP10 (bone morphogenetic protein 10). Further, the present invention relates to a therapeutic agent for hypertension and a hypertensive disease containing an antagonist for at least one of BMP10 and a BMP9/BMP10 heterodimer, a diagnostic agent or a pharmaceutical composition for a disease associated with human BMP10, an immunological detection method or a measurement method for human BMP10 using the antagonist, and use of the antagonist for producing a pharmaceutical composition for treating hypertension and a hypertensive disease.Type: GrantFiled: December 12, 2018Date of Patent: November 1, 2022Assignee: KYOWA KIRIN CO., LTD.Inventors: Hiroyuki Ariyama, Shinya Ogawa, Tetsuya Kitayama, Takenao Yamada
-
Publication number: 20220340642Abstract: An object of the present invention is to provide a DcR3 variant that has binding activity (preferably neutralizing activity) to a ligand of DcR3, and that results in a decreased amount of aggregates as compared to wild-type DcR3 when produced using a cell derived from a mammal as a host, and/or that exhibits improved in vivo kinetics; a DNA encoding the DcR3 variant; a vector including the DNA; a transformant obtained by introducing the vector; a method for producing a variant using the transformant; and a prophylactic or therapeutic agent for an autoimmune disease, an inflammatory disease or an allergic disease including the variant as an active ingredient, and, in order to achieve the object, the present invention provides a DcR3 variant including a part of DcR3 and a part of a TNF superfamily molecule.Type: ApplicationFiled: September 11, 2020Publication date: October 27, 2022Applicant: KYOWA KIRIN CO., LTD.Inventors: Akiko KANAI, Hitomi HOSOMI, Sakiko YONEZAWA
-
Patent number: 11471533Abstract: The present invention provides a compound represented by formula (I) usable as a cationic lipid that facilitates introduction of a nucleic acid, for example, into a cell, and a composition or the like containing the compound.Type: GrantFiled: September 27, 2017Date of Patent: October 18, 2022Assignee: KYOWA KIRIN CO., LTD.Inventors: Shintaro Hosoe, Hayato Yabuuchi
-
Publication number: 20220324945Abstract: An object of the present invention is to provide, as a method for producing an antibody at a lower cost than the prior art, a method for purifying an antibody in a non-adsorption mode using an inorganic compound containing silicon dioxide and aluminum oxide, a method for producing an antibody comprising the purification method, and an antibody produced by the production method, and the like. The present invention relates to a method for purifying an antibody in a non-adsorption mode using an inorganic compound containing silicon dioxide and aluminum oxide, a method for producing an antibody comprising the purification method, and an antibody produced by the production method.Type: ApplicationFiled: July 29, 2020Publication date: October 13, 2022Applicant: Kyowa Kirin Co., Ltd.Inventors: Yasunari ESHIMA, Takashi ISHIHARA
-
Patent number: 11466272Abstract: The present invention provides a double-stranded nucleic acid consisting of a sense-strand nucleic acid and an antisense-strand nucleic acid and comprising a double-strand region having at least 11 base pairs, for suppressing expression of APCS gene, in which an oligonucleotide chain having a chain length of at least 17 nucleotides and at most 30 nucleotides in the antisense-strand nucleic acid is complementary to a target APCS mRNA sequence comprising a base sequence set forth in any one of SEQ ID NOS: 1288 to 1930.Type: GrantFiled: May 31, 2018Date of Patent: October 11, 2022Assignee: KYOWA KIRIN CO., LTD.Inventors: Hiroyuki Ariyama, Takuya Murakami, Takashi Imaeda, Tatsuya Miyazawa
-
Patent number: 11447471Abstract: An object of the present invention is to provide an ?,?-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The ?,?-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, “A” represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents —O—, —S—, —SO2—, —NRX1— (wherein, RX1 represents hydrogen atom or lower alkyl), —CHRX2— (wherein, RX2 represents hydrogen atom or hydroxy), —CH?CH—, ?CO— or —NH—CO—, and n1 and n2 are the same or different, and each represents 0 or 1].Type: GrantFiled: June 22, 2018Date of Patent: September 20, 2022Assignee: KYOWA KIRIN CO., LTD.Inventors: Tomohiro Danjo, Hiroki Yamada, Takahiro Nakajima
-
Publication number: 20220289857Abstract: An antibody or antigen binding fragment thereof that binds to a Fn14, wherein the antibody or antigen binding fragment thereof is an antagonist and non-agonist of Fn14.Type: ApplicationFiled: December 19, 2019Publication date: September 15, 2022Applicant: KYOWA KIRIN CO., LTD.Inventors: Aihua SONG, Andrew John MCKNIGHT, Rachel Soloff NUGENT, John Lorca LAUDENSLAGER, Giuseppe DESTITO, Sarah Sunrise BUBECK, Shinya OGAWA, Yuji YAMAZAKI, David MILLS, Aruna BITRA, Dirk Michael ZAJONC
-
Publication number: 20220259328Abstract: An object of the present invention is to provide a bispecific antibody, which binds to CD40 and FAP and exhibits a strong CD40 agonistic activity in a FAP dependent manner or a bispecific antibody fragment thereof, and the like. The present invention relates to a bispecific antibody, which is a bispecific antibody containing an IgG portion including a first antigen binding domain and also containing a second antigen binding domain, and binding to human CD40 and human FAP, wherein the C terminus of a heavy chain of the IgG portion binds to the second antigen binding domain either directly or via a linker, or a bispecific antibody fragment thereof, and the like.Type: ApplicationFiled: May 15, 2020Publication date: August 18, 2022Applicant: Kyowa Kirin Co., Ltd.Inventors: Yuta TEZUKA, Aya OSANAI, Katsuaki USAMI, Harue NISHIYA
-
Publication number: 20220220216Abstract: An object of the present invention is to provide a bispecific antibody including an antigen binding domain that binds to CD40 and an antigen binding domain that binds to GPC3. The present invention relates to a bispecific antibody including an antigen binding domain that binds to CD40 and an antigen binding domain that binds to GPC3, a bispecific antibody fragment thereof, a DNA encoding the bispecific antibody or the bispecific antibody fragment, a vector containing the DNA, and the like.Type: ApplicationFiled: May 15, 2020Publication date: July 14, 2022Applicant: Kyowa Kirin Co., Ltd.Inventors: Yoshiki SUMITOMO, Masayuki KAI
-
Publication number: 20220202920Abstract: A composition containing antithrombin and a method for treating preeclampsia are disclosed. The method includes administering antithrombin or a composition including antithrombin to a subject in need of preeclampsia treatment. The subject may have blood antithrombin activity of 100% or less. The composition containing antithrombin may be administered to a subject with preeclampsia, who has blood antithrombin activity of 100% or less and the like.Type: ApplicationFiled: February 10, 2020Publication date: June 30, 2022Applicant: KYOWA KIRIN CO., LTD.Inventors: Yoshihide NAKAMURA, Takashi MURAYAMA, Kenichi TAKAGI, Ryutaro SHIMAZAKI, Yuichi ENDO, Hironori KANDA, Kayoko MOTOYAMA, Masaya KATO, Shunichiro ORIHARA, Tomoko TANAKA
-
Publication number: 20220168311Abstract: A therapeutic agent for Parkinson's disease containing istradefylline as an effective ingredient being characterized in exhibiting more expression of a shortening effect of the OFF time by administration to a patient of Parkinson's disease of 65 or more years old as compared with administration to a patient of Parkinson's disease of younger than 65 years old.Type: ApplicationFiled: March 19, 2020Publication date: June 2, 2022Applicant: KYOWA KIRIN CO., LTD.Inventors: Tomoyuki KANDA, Akihisa MORI, Hiroki KITABAYASHI, Takanobu NOMURA, Nobutaka HATTORI
-
Patent number: 11332455Abstract: The present invention provides an ?,?-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): [wherein, “A” represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents —O—, —S—, —SO2—, —NRX1— (wherein, RX1 represents hydrogen atom or lower alkyl), —CHRX2— (wherein, RX2 represents hydrogen atom or hydroxy), —CH?CH—, —CO— or —NH—CO—, and n1 and n2 are the same or different, and each represents 0 or 1].Type: GrantFiled: September 28, 2020Date of Patent: May 17, 2022Assignee: KYOWA KIRIN CO., LTD.Inventors: Tomohiro Danjo, Katsuaki Fujiwara, Tomoyuki Nishikawa, Takahiro Nakajima, Nobumasa Otsubo, Toshihiro Seike
-
Publication number: 20220135691Abstract: A therapeutic or prophylactic agent for radiation damage associated with radiation exposure, comprising an eosinophil-removing agent as an active ingredient and the like are provided as a technique for efficiently treating or preventing radiation damage associated with radiation exposure. According to the therapeutic or prophylactic agent comprising an eosinophil-removing agent according to the present invention, by suppressing migration and/or infiltration into target tissue and/or proliferation in the tissue of eosinophils and/or inhibiting the activity or function of the eosinophils, pathological conditions such as inflammatory responses and fibrosis of tissue can be suppressed to effectively treat or prevent radiation damage. Moreover, effective radiation therapy can be performed by suppressing radiation damage.Type: ApplicationFiled: November 18, 2021Publication date: May 5, 2022Applicants: Kyowa Kirin Co., Ltd., The University of TokyoInventors: Kazuki OKADA, Kiyotoshi Mori, Satoshi Uematsu, Naoki Takemura
-
Publication number: 20220127605Abstract: The present invention provides a nucleic acid conjugate represented by the following formula 1: wherein X is a double-stranded nucleic acid consisting of a sense strand and an antisense strand and comprising a duplex region of at least 11 base pairs, wherein in the double-stranded nucleic acid, an oligonucleotide strand having a chain length of 17 to 30 nucleotides in the antisense strand is complementary to any of target APCS mRNA sequences described in Tables 1-1 to 1-13, and the 3? end or the 5? end of the sense strand binds to S3, L1 and L2 are each independently sugar ligand, and Si, S2 and S3 are each independently a linker.Type: ApplicationFiled: December 2, 2019Publication date: April 28, 2022Applicant: KYOWA KIRIN CO., LTD.Inventors: Hiroto IWAI, Takashi IMAEDA, Hiroyuki ARIYAMA, Takuya MURAKAMI
-
Patent number: 11298326Abstract: The present invention provides nucleic acid-containing lipid nanoparticles containing a lipid (lipid A) which has a hydrophilic unit having a single quaternary ammonium group, and three independent, optionally substituted hydrocarbon groups, a lipid derivative or fatty acid derivative of a water-soluble polymer, and a nucleic acid.Type: GrantFiled: March 24, 2016Date of Patent: April 12, 2022Assignee: KYOWA KIRIN CO., LTD.Inventors: Kentaro Hatanaka, Nobuhiro Yagi, Takeshi Kuboyama, Kaori Yagi, Shintaro Hosoe
-
Publication number: 20220088011Abstract: The present invention provides a method for treating a tumor comprising administering an effective amount of an antibody which specifically binds to human CC chemokine receptor 4, human epidermal growth factor receptor 2, human CD20, or epidermal growth factor receptor, and an indoleamine 2,3-dioxygenase inhibitor to a human in need thereof, and the like.Type: ApplicationFiled: November 5, 2021Publication date: March 24, 2022Applicant: KYOWA KIRIN CO., LTD.Inventors: Akihiro TOKUNAGA, Toshihiko ISHII, Motoya MIE, Munetoshi ANDO